Condition: Diffuse Midline Glioma, H3 K27-Altered · Metastatic Malignant Neoplasm in the Central Nervous System · Recurrent Diffuse Intrinsic Pontine Glioma · Sponsor: Children's Oncology Group
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Children's Hospital of Alabama | Birmingham, Alabama, United States | Recruiting |
| Phoenix Childrens Hospital | Phoenix, Arizona, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Children's Hospital of Orange County | Orange, California, United States | Recruiting |
| UCSF Medical Center-Mission Bay | San Francisco, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Johns Hopkins All Children's Hospital | St. Petersburg, Florida, United States | Recruiting |
| Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta, Georgia, United States | Recruiting |
| Lurie Children's Hospital-Chicago | Chicago, Illinois, United States | Recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| Riley Hospital for Children | Indianapolis, Indiana, United States | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04870944